Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Evommune, Inc.NYSE: EVMN
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables grows 442.5% year over year
Q1 FY2026 accounts payables of $3.75M (cash outflow) rose 442.5% year over year.
Context
- Accounts payables amounted to 6.4% of revenue in FY2025, down 86.5 pp from a year earlier.
- Accounts payables increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (837K) USD
- Year-over-year change
- -112.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (837K) | -112.9% |
| FY2024 | 2024-12-31 | 6.51M | +5104.8% |
| FY2023 | 2023-12-31 | 125K | — |
Accounts Payables vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 accounts payables of $3.9M is the 4th largest of the 10 companies compared; the peer median is $215K.
- Accounts payables amounts to 39.0% of revenue for EVMN, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $45.36M | +357.1% | — | 17.1% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $38.5M | -26.8% | — | 1.4% |
| LTM Jun 2026 | $14.4M | +31.4% | — | 5.0% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $3.9M | — | — | 39.0% |
| LTM Mar 2026 | $3.04M | -297.9% | — | 3.9% | |
| LTM Mar 2026 | $1.59M | +8.7% | — | 1.1% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $1.01M | +447.4% | — | — |
| LTM Mar 2026 | $274K | -97.7% | +57.5% | 3.6% | |
| LTM Mar 2026 | $215K | +111.0% | — | 0.7% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $83K | +107.6% | — | — |
| Peer median (excluding EVMN) | $215K | +31.4% | +57.5% | 3.6% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 3.34M | 7.42M | (4.12M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 125K | 6.51M | (837K) |
| Other Working Capital | 3.22M | 918K | (3.28M) |
| Other Non-Cash Items | (261K) | (98K) | (4.84M) |
| Operating Cash Flow | (29.97M) | (58.2M) | (76.44M) |
| Capital Expenditures | (118K) | (88K) | (235K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (91.31M) | (90.26M) | (199.17M) |
| Sales of Investments | 43M | 86.35M | 84.1M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (48.43M) | (3.99M) | (115.31M) |
| Debt Repayment | 0 | 0 | (373K) |
| Common Stock Issued | 63.98M | 49.84M | 222.36M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (230K) | (423K) | (1.22M) |
| Financing Cash Flow | 63.75M | 49.42M | 220.76M |
| Effect of Forex Changes | 43.67M | (1) | (1.21M) |
| Net Change in Cash | 29.02M | (12.77M) | 27.81M |
| Free Cash Flow | (30.09M) | (58.28M) | (76.68M) |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.